168 related articles for article (PubMed ID: 33086690)
1. Adjuvant Antitumor Immunity Contributes to the Overall Antitumor Effect of Pegylated Liposomal Doxorubicin (Doxil
Takayama T; Shimizu T; Lila ASA; Kanazawa Y; Ando H; Ishima Y; Ishida T
Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33086690
[TBL] [Abstract][Full Text] [Related]
2. Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model.
Shimizu T; Abu Lila AS; Nishio M; Doi Y; Ando H; Ukawa M; Ishima Y; Ishida T
Cancer Sci; 2017 Sep; 108(9):1864-1869. PubMed ID: 28643902
[TBL] [Abstract][Full Text] [Related]
3. A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes.
El Sayed MM; Shimizu T; Abu Lila AS; Elsadek NE; Emam SE; Alaaeldin E; Kamal A; Sarhan HA; Ando H; Ishima Y; Ishida T
Int J Pharm; 2022 Mar; 615():121539. PubMed ID: 35124114
[TBL] [Abstract][Full Text] [Related]
4. Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models.
Ito K; Hamamichi S; Asano M; Hori Y; Matsui J; Iwata M; Funahashi Y; Umeda IO; Fujii H
Cancer Sci; 2016 Jan; 107(1):60-7. PubMed ID: 26509883
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil).
Tsukioka Y; Matsumura Y; Hamaguchi T; Koike H; Moriyasu F; Kakizoe T
Jpn J Cancer Res; 2002 Oct; 93(10):1145-53. PubMed ID: 12417045
[TBL] [Abstract][Full Text] [Related]
6. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
8. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
[TBL] [Abstract][Full Text] [Related]
9. Targeting the leptin receptor: To evaluate therapeutic efficacy and anti-tumor effects of Doxil, in vitro and in vivo in mice bearing C26 colon carcinoma tumor.
Amiri Darban S; Nikoofal-Sahlabadi S; Amiri N; Kiamanesh N; Mehrabian A; Zendehbad B; Gholizadeh Z; Jaafari MR
Colloids Surf B Biointerfaces; 2018 Apr; 164():107-115. PubMed ID: 29413587
[TBL] [Abstract][Full Text] [Related]
10. PNC27 anticancer peptide as targeting ligand significantly improved antitumor efficacy of Doxil in HDM2-expressing cells.
Darban SA; Badiee A; Jaafari MR
Nanomedicine (Lond); 2017 Jun; 12(12):1475-1490. PubMed ID: 28565974
[TBL] [Abstract][Full Text] [Related]
11. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody.
ElBayoumi TA; Torchilin VP
Clin Cancer Res; 2009 Mar; 15(6):1973-80. PubMed ID: 19276264
[TBL] [Abstract][Full Text] [Related]
12. Doxil chemotherapy plus liposomal P5 immunotherapy decreased myeloid-derived suppressor cells in murine model of breast cancer.
Navashenaq JG; Zamani P; Nikpoor AR; Tavakkol-Afshari J; Jaafari MR
Nanomedicine; 2020 Feb; 24():102150. PubMed ID: 31931230
[TBL] [Abstract][Full Text] [Related]
13. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
Rios-Doria J; Durham N; Wetzel L; Rothstein R; Chesebrough J; Holoweckyj N; Zhao W; Leow CC; Hollingsworth R
Neoplasia; 2015 Aug; 17(8):661-70. PubMed ID: 26408258
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin Expands in Vivo Secretion of Circulating Exosome in Mice.
Emam SE; Ando H; Abu Lila AS; Kobayashi S; Shimizu T; Okuhira K; Ishima Y; Ishida T
Biol Pharm Bull; 2018; 41(7):1078-1083. PubMed ID: 29962402
[TBL] [Abstract][Full Text] [Related]
15. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models.
Peer D; Margalit R
Neoplasia; 2004; 6(4):343-53. PubMed ID: 15256056
[TBL] [Abstract][Full Text] [Related]
16. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K
Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
18. AR13 peptide-conjugated liposomes improve the antitumor efficacy of doxorubicin in mice bearing C26 colon carcinoma; in silico, in vitro, and in vivo study.
Biabangard A; Asoodeh A; Jaafari MR; Moosavi Baigi F
Toxicol Appl Pharmacol; 2023 May; 466():116470. PubMed ID: 36933622
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model.
Chang YJ; Chang CH; Yu CY; Chang TJ; Chen LC; Chen MH; Lee TW; Ting G
Nucl Med Biol; 2010 Jan; 37(1):95-104. PubMed ID: 20122674
[TBL] [Abstract][Full Text] [Related]
20. Investigation into the role of tumor-associated macrophages in the antitumor activity of Doxil.
Banciu M; Schiffelers RM; Storm G
Pharm Res; 2008 Aug; 25(8):1948-55. PubMed ID: 18523874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
